Australian Biotech

In the words of George Orwell, “But if thought corrupts language, language can also corrupt thought.” Be under no illusion that the confected outrage on PhRMA's two-month-old submission, virtually unchanged in a decade, risks poisoning the well and corrupting any thoughtful dialogue on PBS reform.

“I am honoured to be appointed as Chair of Medicines Australia and I look forward to working with the Medicines Australia Board and Executive to continue championing the latest advancements in medicine, and advocating for patients to have fast, universal access to new treatments."

A total victory for pharmacy with the prime minister's appearance at their showcase annual event. We discuss the confected outrage over US interest in the PBS, which is hardly new, and why the industry needs to lead this debate because its reputation and change agenda are being trashed.

Cystic Fibrosis NZ says the path is clear for Pharmac to expand access to Vertex's TRIKAFTA for aged two to five following a new Medsafe approval.

Less than 100 hours ago, Health Minister Mark Butler boasted of his need to 'nudge' HTA processes he had previously described as "clunky" and responsible for preventable deaths. He now defends the inviolability of the system against criticism from the US-based industry that parrots his own. Confused?

Sigma has announced its full-year results for the 12 months ending 31 January 2025, which was the final before its recently completed merger with Chemist Warehouse.

“This is a significant step towards relieving the financial burden of ill health and chronic conditions and making sure people can get the medicine they need," said National President Pharmacy Guild of Australia, Professor Trent Twomey.

What is the problem with international criticism of Australia's use of HTA and pricing policy? This is the framework Health Minister Mark Butler described as "clunky" while acknowledging its responsibility for preventable deaths.

Patients contributing to Australia's HTA processes are forced to use an online portal, do not know how their input is used, and receive no follow-up or feedback. Compare that to the role of patient input under the US government's price negotiation power for prescription medicines.

Since 2000, when it started in a makeshift basement laboratory, QBiotics has spent 25 years focused on discovering and developing novel cell signalling small molecules for challenging medical conditions.

Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has raised a total of $2.72 million via the exercise of 45,349,978 listed options.